Three more biotechs price their Nasdaq IPOs AgomAb, SpyGlass, and Veradermics have all set the terms for their IPOs this week, looking to raise somewhere between around $150m and $200m.

#AgomAbTherapeutics, #SpyGlassPharma, and #Veradermics have all set the terms for their initial pubic offerings on the #Nasdaq, looking to raise somewhere between $150 million and $200 million.

Agomab and Spyglass push the IPO button Glimmers of a renewal of biotech IPO activity in 2026 have continued with the news that AgomAb and SpyGlass Pharma are sizing up investor interest.

Glimmers of a resurgence in #biotech #IPO activity in 2026 have continued with the news that two more companies – Belgium's #AgomAbTherapeutics and #SpyGlassPharma of the US – are sizing up #investorinterest.

pharmaphorum.com/news/agomab-...

More $$ Raises: #David $75M Series A; #SpyGlassPharma $75M Series D; #FlockFreight $60M Series E

Acquisitions: #AMD > #Brium; #Datasite > #Grata; #Genpact > #XponentlData; #IBM > #SeekAI; #Him&HersHealth > #Zava; #IntelligentTechnicalSolutions > #BlackBreach; #JohnDeere > #Sentera